Evaluate the Safety and Effectiveness of Using Echogenic Embolic Agent for Embolization of Prostate Artery for Treatment of Men With BPH (PAE CEUS)

Inclusion Criteria: * Potential participants will be identified in the Urology Clinic diagnosed with benign prostatic hypertrophy and fit the criteria - 1. Have received a diagnosis of BPH with moderate to severe LUTS, as determined by IPSS 2. Are greater than 50 years of age 3. Have had a pelvic examination by a urologist within the previous 6 months 4. Have been refractory to medical therapy for 6 months, or have refused medical therapy 5. Have a Qmax below 15 mL/s or acute urinary retention 6. Prostate larger than 40 cm3 7. Willing and able to provide written informed consent. Exclusion Criteria: * Patients will be excluded from this study if they meet any of the following criteria: 1. Total serum PSA \> 10.0 ng/mL at screening 2. Advanced atherosclerosis and tortuosity of the iliac arteries 3. PVR \> 250 mL 4. Use of phytotherapy for BPH within 2 weeks of screening visit 5. Secondary renal insufficiency (due to prostatic obstruction) 6. Chronic renal failure (glomerular filtration rate \< 60) 7. Large bladder diverticula or bladder stones 8. Have claustrophobia or other contraindications to the performance of the pre- and post-procedure MRI studies, including but not confined to the presence of metal implants, metal plates, bone pins, bone screws, neurostimulators, cardiac pacemakers, aneurysm clips, cochlear or retinal implants, or permanent hearing aids 9. Have compromised hematopoietic function (hemoglobin \< 100 g/L; lymphocyte count \< 500 x106/L; neutrophil count \< 1.5 x 109/L; platelet count \< 50 x 109/L 10. Have had a documented anaphylactic reaction to a drug or anesthetic, or an allergic reaction to iodine contrast media not controlled by antihistamines or steroids 11. Have received other investigational drugs or who have had experimental therapy within the past 4 weeks or are participating in any other concurrent experimental therapy 12. Have abnormal coagulation profiles 13. Are allergic to bovine collagen 14. Are allergic to Perflutren 15 Are unable to comply with the follow up requirements of the study 16 Have serious cardiopulmonary compromise